<DOC>
	<DOCNO>NCT01487174</DOCNO>
	<brief_summary>This study involve treatment KD019 erlotinib patient Non-small cell lung cancer ( NSCLC ) progress first- second- line chemotherapy . It hypothesize KD019 prolong survival compare erlotinib .</brief_summary>
	<brief_title>KD019 Versus Erlotinib Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- Second-Line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>For Eligibility subject must : fail one two previous course therapy . active brain metastasis . Treated nonactive brain metastasis acceptable . receive Epidermal Growth Factor Receptors inhibitor ( Tarceva [ erlotinib ] Iressa [ gefitinib ] ) past . demonstrate progressive disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>